Table 2.
Univariate Cox regression analysis of overall survival and progression-free survival in patients with limited-stage small-cell lung cancer.
| Characteristics | Overall survival | Progression-free survival | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Group (IO + RT + CT vs IO + CT) | 0.26 (0.09–0.72) | 0.01 | 0.48 (0.21–1.09) | 0.078 |
| Group (RT + CT vs IO + CT) | 0.21 (0.09–0.46) | <0.001 | 0.43 (0.22–0.84) | 0.013 |
| Sex (male vs female) | 1.26 (0.55–2.9) | 0.59 | 0.88 (0.48–1.61) | 0.681 |
| Age | 1.01 (0.97–1.05) | 0.576 | 1.01 (0.97–1.04) | 0.69 |
| Smoke (never/unknown vs former/current) | 0.92 (0.43–1.98) | 0.835 | 1.21 (0.68–2.16) | 0.517 |
| BMI | 1.04 (0.94–1.16) | 0.459 | 1.02 (0.93–1.11) | 0.706 |
| T (T3–4 vs T1–2) | 0.86 (0.43–1.71) | 0.66 | 0.9 (0.52–1.55) | 0.703 |
| N (N1-3 vs N0) | 3.15 (0.43–23.04) | 0.259 | 1.65 (0.4–6.81) | 0.49 |
| TNM (III vs I-II) | 1.25(0.44–3.57) | 0.673 | 0.79 (0.35–1.78) | 0.575 |
| ALB | 1.04 (0.94–1.15) | 0.446 | 0.989 (0.913–1.07) | 0.775 |
| LDH | 1 (0.997–1.003) | 0.865 | 1.001 (0.999–1.003) | 0.311 |
| CRP | 1.013 (0.999–1.028) | 0.069 | 1.007 (0.994–1.02) | 0.311 |
| NLR | 1.193 (0.951–1.496) | 0.128 | 1.142 (0.944–1.38) | 0.172 |
| SII | 1.001 (1–1.002) | 0.194 | 1.001 (1–1.001) | 0.097 |
| dNLR | 1.405 (1.012–1.951) | 0.042 | 1.246 (0.938–1.655) | 0.129 |
| NSE | 1 (0.991–1.009) | 0.96 | 1.006 (0.999–1.013) | 0.071 |
| pro-GRP | 1 (1–1) | 1 | 1 (1–1) | 0.647 |
ALB, albumin; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; CT, chemotherapy; dNLR, derived neutrophil-to-lymphocyte ratio; HR, hazard ratio; IO, immunotherapy; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; NSE, neuron-specific enolase; pro-GRP, progastrin-releasing peptide; RT, radiotherapy; SII, systemic inflammatory index.